Scioderm

Scioderm, Inc. is a pharmaceutical company that developed topical products for treating rare diseases that are characterized by fragile skin and recurrent blister formation.

Scioderm's lead product candidate Zorblisa is a novel, late-stage, proprietary topical cream and therapy for EB. Zorblisa had established positive proof-of-concept in Phase 2 studies for the treatment of lesions in patients suffering from EB, and it was investigated in a Phase 3 study to support global regulatory approvals. Zorblisa was one of the first products to receive FDA breakthrough therapy designation in 2013, and was the first-ever treatment in EB clinical studies to show significant benefit in wound closure across all major EB subtypes.

The company had been acquired by Amicus Therapeutics, Inc. in September 2015. Amicus Therapeutics is a patient-dedicated biotechnology company that focuses on discovering, developing and delivering high-quality medicines for people who are living with rare genetic diseases.

Amicus, together with Scioderm, was developing an investigational topical treatment (SD-101) for people with Epidermolysis Bullosa (EB), which is a rare genetic connective tissue disorder.